Protoporphyrin IX enhancement by 5-aminolaevulinic acid peptide derivatives and the effect of RNA silencing on intracellular metabolism

L Bourré 1, F Giuntini 2, IM Eggleston 2, M Wilson 3 and AJ MacRobert * 1

1 Division of Surgical and Interventional Sciences, National Medical Laser Centre, UCL Medical School, University College London, Charles Bell House, 67–73 Riding House St, London W1W 7EJ, UK; 2 Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, UK; 3 Division of Microbial Diseases, UCL Eastman Dental Institute, University College London, 256 Grays Inn Road, London WC1X 8LD, UK

Intracellular generation of the photosensitiser, protoporphyrin IX, from a series of dipeptide derivatives of the haem precursor, 5-aminolaevulinic acid (ALA), was investigated in transformed PAM212 murine keratinocytes, together with studies of their intracellular metabolism. Porphyrin production was substantially increased compared with equimolar ALA using N-acetyl terminated phenylalanyl, leucinyl and methionyl ALA methyl ester derivatives in the following order: Ac-L-phenylalanyl-ALA-Me, Ac-L-methionyl-ALA-Me and Ac-L-leucinyl-ALA-Me. The enhanced porphyrin production was in good correlation with improved photocytotoxicity, with no intrinsic dark toxicity apparent. However, phenylalanyl derivatives without the acetyl/acyl group at the N terminus induced significantly less porphyrin, and the replacement of the acetyl group by a benzylthioacetyl group resulted in no porphyrin production. Porphyrin production was reduced in the presence of class-specific protease inhibitors, namely serine protease inhibitors. Using siRNA knockdown of acylpeptide hydrolase (ACPH) protein expression, we showed the involvement of ACPH, a member of the prolyl oligopeptidase family of serine peptidases, in the hydrolytic cleavage of ALA from the peptide derivatives. In conclusion, ALA peptide derivatives are capable of delivering ALA efficiently to cells and enhancing porphyrin synthesis and photocytotoxicity; however, the N-terminus state, whether free or substituted, plays an important role in determining the biological efficacy of ALA peptide derivatives.

British Journal of Cancer (2009) 100, 723–731. doi:10.1038/sj.bjc.6604928 www.bjcancer.com
Published online 24 February 2009
© 2009 Cancer Research UK

Keywords: photodynamic therapy; aminolaevulinic acid; ALA derivatives; acylpeptide hydrolase (ACPH, EC 3.4.19.1); siRNA silencing; protoporphyrin IX

Photodynamic therapy (PDT) is a promising modality for cancer treatment that utilizes tumour-specific accumulation of a photosensitiser, followed by irradiation with light at an appropriate wavelength (Bonnett, 1995). The use of 5-aminolaevulinic acid (ALA) for PDT has received considerable interest owing to the metabolism of ALA through the haem biosynthetic pathway (Peng et al., 1997) to the photosensitiser protoporphyrin IX (PpIX). Following the exogenous administration of ALA, PpIX is generated intracellularly, which can then be activated by visible light for PDT treatment. ALA-PDT does exhibit a degree of intrinsic tumour selectivity owing to differing tumour levels of enzymes in the haem pathway (e.g. ferrochelatase) leading to higher tumour PpIX levels. The principal advantages of ALA-PDT are the short duration of skin photosensitivity and its efficacy using both topical and oral administration (Peng et al., 1997; Brown et al., 2004).

A significant drawback of ALA-PDT is the fact that ALA is a zwitterion at physiological pH resulting in low lipid solubility and limiting passage through biological barriers such as cellular membranes. To overcome this problem, several chemical approaches have been attempted to improve the incorporation of ALA and also its selectivity. One approach has been to use more lipophilic ALA derivatives, such as alkyl or ethyleneglycol esters, which are potential substrates for cellular esterases (Kloek and Beijersbergen, 1996; Gaullier et al., 1997; Berger et al., 2000; Uehlinger et al., 2000), or different delivery systems including dendrimers (Battah et al., 2001, 2006; Di Venosa et al., 2006), or liposomes (Casas et al., 2002; Casas and Batlle, 2006). 5-Aminolaevulinic acid prodrug ester derivatives have been widely studied (Kloek and Beijersbergen, 1996; Peng et al., 1996; Gaullier et al., 1997; Kloek et al., 1998; Casas et al., 1999; Eleouet et al., 2000; Brunner et al., 2003; Lopez et al., 2004), in particular the methyl and hexyl ester derivatives, and approval has been granted for the treatment of actinic keratosis and basal cell carcinoma using the methyl ester derivative in Europe and Australia. The use of alkyl esters of ALA results in a nonselective distribution of ALA in all cell types, but with an increased PpIX production (Webber et al., 1997; Uehlinger et al., 2000) in tumour cells. In this regard, Casas et al. (1999) and Berger et al. (2000, 2003) have conjectured that the
incorporation of 5-ALA into a short peptide derivative would provide a suitable means of both facilitating transdermal delivery and also improved targeting to cancerous cells.

In an attempt to improve uptake and cell selectivity of ALA and its derivatives, we investigated PpIX formation and metabolism mechanisms using peptide ALA prodrugs that represent potential substrates for cell-surface and cytoplasmic peptidases and esterases. A recent investigation of ALA prodrugs showed that the L-enantiomer of Ac-Phe-ALA-Me, 1, was capable of delivering ALA to cells, with an enhancement of PpIX and PDT effectiveness, comparable with the results obtained with the hexyl ester derivative, ALA-Hex (Bourré et al., 2008). The ALA residue was masked on one side through a peptide bond and on the other side through an ester linkage, which were then cleaved enzymatically within the cells to liberate the ALA. We also showed that the D-enantiomer did not induce any PpIX production, which would be consistent with the stereospecific enzymatic cleavage acting only on the L-forms of such prodrugs.

In this study, we have focused on several ALA peptide derivatives using different amino acids and have studied the influence of structural modification at the N terminus by changing the N-terminal blocking group. We then studied the metabolism mechanism involved in the release of ALA using class protease inhibitors and silencing of mammalian acylpeptide hydrolase activity (ACPH, EC 3.4.19.1) using small interfering RNA (siRNA) technology. Acylpeptide hydrolase, a member of the prolyl oligopeptidase family of serine peptidases, is an exo-peptidase that removes acylated amino-acid residues from the N terminus of oligopeptides.

MATERIALS AND METHODS

Chemicals

5-Aminolaevulinic acid was purchased from Sigma-Aldrich Ltd (Gillingham, UK).

The structures of ALA peptide derivatives are shown in Figure 1. The synthesis of compounds 1–5 (Rogers et al., 2005) and 8 (Bourré et al., 2008) has already been reported. Compounds 6, 9 and 10 were synthesised according to the same procedure with minor modifications. Stock solutions of compounds 1 and 2 were prepared by dissolving at 10 mM in 0.01 M HCl and stored at −20°C. Compound 3 was dissolved at 100 mM in 0.1 M HCl solution and stored at −20°C.

Cell culture

The spontaneously transformed murine keratinocyte cell line, PAM212 (obtained from Professor R Groves, King’s College, London), was cultured in RPMI-1640 medium (Gibco BRL, Life Technologies Ltd, Paisley, UK) containing l-glutamine (2 mM) and phenol red, supplemented with 10% foetal calf serum (FCS; Sigma-Aldrich Ltd) and penicillin and streptomycin (500 U ml⁻¹ and 0.5 mg ml⁻¹; Gibco BRL). The cells were routinely grown as monolayers in 75-cm² culture flasks (TPP; Helena Bioscience, Gateshead, UK) at 37°C, 5% CO₂ atmosphere until confluent.

Porphyrin synthesis determination

Cells were seeded into γ-sterilised 96-well plates (Orange Scientific, Triple Red Laboratory Technologies, Long Crendon, UK) at a density of 5 × 10⁴ cells per well for 48 h. After removing the culture medium, the wells were washed with PBS and incubated with freshly prepared solutions of ALA or ALA peptide derivatives 1–10: 0.1 ml of serum-free medium containing varying prodrug concentrations was added to a designated series of wells. Each plate contained control wells with cells but without added drug for the determination of the background reading and reference wells containing cells incubated with the same ALA concentrations. For drug incubation, serum-free medium was used as serum is known to cause the release of PpIX from cells, thus resulting in the loss of fluorescence signal (Kloek et al., 1998).

![Figure 1](image-url) General structure of ALA peptide derivatives.
The fluorescence signal from each well was measured with a spectrometer Perkin Elmer LS 50B fluorescence spectrometer (Perkin Elmer, Beaconsfield, UK) using 410-nm excitation and 635-nm emission wavelengths, with slit widths set to 10 nm and the internal 530 nm longpass filter used on the emission side; spectral scans were recorded between 600 and 750 nm to check for the presence of any porphyrins other than PpIX (Battah et al, 2006). The mean fluorescence intensity (expressed in arbitrary units) was calculated after subtraction of the control values. Intensity calibrations were performed using rhodamine B embedded in a Perspex disc as a standard.

Photodynamic treatment

Cells were seeded into 96-well plates at a density of approximately 2 x 10⁴ cells per well. Following incubation for 48 h, the cells were washed with PBS, and 0.1 ml of solutions containing ALA, 1, 6, 7, 8 and 9 at 0.01 mM were added to their designated wells for 4-h incubation periods. The plates were irradiated with a fluence of 2 J cm⁻² using a LumiSource lamp (PCI Biotech, Oslo, Norway) that emits a uniform field of low-power blue light over an area of 14 x 32 cm. Peak output is around 420 nm, which overlaps well with the PpIX Soret band. Immediately following irradiation, the medium was replaced and cells were incubated for a further 24 h. Cell cytotoxicity was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay: cells were incubated with medium containing MTT (1 mg/ml dissolved in full RPMI-1640 medium) for 3 h. The insoluble end product (formazan derivatives) was dissolved in 0.1 ml of dimethylsulphoxide after removing the medium. Ultraviolet absorption was quantified at 570 nm using a 96-well plate reader (MR 700 Dynatech; Dynex, Worthing, UK). The mean cell survival was calculated for each prodrug at every concentration tested and allowed to grow for 72 h, 37°C, 5% CO₂, before experimentation. The PpIX synthesis was assessed after incubation with 0.5 mM of ALA or 1 during 4 h, and then washed with PBS. One ml of CellLytic (Sigma-Aldrich Ltd) was added and incubated during 15 min at room temperature, and then the cells were mechanically scraped. Cell extracts were centrifuged at 1800 g for 10 min to remove the cell debris, and the supernatant containing the PpIX was collected. The fluorescence of extracted PpIX was measured as described earlier.

Statistical analysis

The results are displayed graphically, with error bars representing standard deviations. Differences are considered to be significant using the unpaired t-test.

RESULTS

PpIX synthesis determination

The PpIX generated by exposure to compounds 1–6, compared with ALA, is shown in Figure 2A and B. At 0.01 mM (Figure 2A), ALA was not able to produce any measurable PpIX; however, a high amount of PpIX was produced with 1. Compounds 3, 5 and 6 also induced some PpIX production but to a lesser extent. However, compounds 2 and 4 were not able to induce measurable PpIX levels at this concentration. Using 0.1 mM (Figure 2B), the level of PpIX was enhanced by a factor 3.5 with 1, 5 and 6 compared with ALA.

Fluorescence pharmacokinetics

The kinetics of intracellular porphyrin fluorescence induced by exposure to compounds 1, 7–9 and ALA in the PAM212 cell line are shown in Figure 3A and B. Fluorescence spectral profiles were consistent with the production of PpIX, and peak emission at 635 nm was used for the pharmacokinetic measurements. Increasing porphyrin levels were observed with increasing incubation times from 2 to 6 h. For the lowest concentration tested, 0.01 mM, no PpIX production was observed with ALA, 8 and 9. However, 1 and 7 induced high levels of PpIX, 1 inducing the higher level regardless of the incubation time. When the concentration was increased to 0.1 mM, all the compounds induced PpIX production, with a significant increase found with 1 and 7. However, peptides 8 and 9, compounds without an acetyl group at the N terminus, induced less PpIX compared with ALA; these results were also observed in human epidermoid carcinoma A431 cells and colon carcinoma Caco-2 cells (data not shown). No significant difference was observed for 1 when the concentration was increased.

Figure 4A shows the results of experiments carried out with compound 10 vs 1 and ALA, to observe the effect of the Z group at the N terminus instead of the acetyl group in compound 1. No PpIX production was observed with 10 compared with ALA.
whatever the incubation time or the concentration used. In Figure 4B, the effect of the presence of the amino acid in the prodrug derivative was studied, and for this purpose, the molecule, Ac-Ala-Ala-Ala-Ala-OH, was synthesised. No PpIX production was observed with Ac-Ala-Ala-Ala-OH compared with ALA or 1, whatever the incubation time or the concentration used.

Photodynamic treatment

The phototoxicity was investigated after 4 h of incubation with 0.01 mM of ALA, 1, 6, 7, 8 and 9. The percentage of cell survival with respect to control cells (without compounds) was calculated and plotted as shown in Figure 5. No dark toxicity was found for any of the compounds. Compounds 1, 6 and 7 exhibited a high photocotoxicity with less than 5% cell survival. However, no photocotoxicity was observed with ALA or compound 1, whatever the incubation time or the concentration used.

Peptidase activities: acylpeptide hydrolase assay

Influence of protease inhibitors To obtain information concerning the enzymatic activities involved in releasing free ALA from the prodrugs, we evaluated PpIX production after incubation with ALA or compound 1 in the presence of class-specific protease inhibitors (Figure 6): protease inhibitor cocktail, aprotinin, AEBSF, 2,2′-bipyridyl, bestatin, E64, leupeptin and captopril.

Aprotinin, bestatin, 2,2′-bipyridyl, E64, leupeptin and captopril had no significant effect. However, the PpIX production was reduced by serine protease inhibitor AEBSF.

Acylpeptide hydrolase assay To confirm ACPH activity in PAM212 cells, we tested the ACPH activity of cell lysates using AcApNA as a substrate (Scaloni et al, 1992b, 1994; Sharma and Ortwerth, 1993; Yamaguchi et al, 1999) and the influence of inhibitors. Acylpeptide hydrolase has earlier been reported to be inactivated with the thiol reagent pHMB (Scaloni et al, 1994) and histidine-modifying reagent DEP (Scaloni et al, 1992b). As shown in Figure 7A and B, the PAM212 cell lysate showed some ACPH activity in the absence of inhibitors. However, the ACPH activity was rapidly and completely inhibited by pHMB (Figure 7A) and moderately by DEP (Figure 7B).

To assess if our peptide produgs are potential substrates for ACPH, we studied the influence of the concentration of the drug on AcApNA hydrolysis (Figure 7C). We evaluated the influence of ALA, phenylalanyl derivative 1 (the most efficient of the peptide derivatives) and Ac-Ala-Ala-Ala-Ala-OH, which is a substrate for ACPH (Krishna and Wold, 1992; Sokolik et al, 1994). 5-Aminolaevulonic acid exerted no significant influence on ACPH activity, whatever the concentration used. The ACPH substrate, Ac-Ala-Ala-Ala-Ala-OH, reduced the ACPH activity by 42 and 47%, respectively, with 5 and 10 mM. Compound 1 exhibited similar effects by a reduction of activity by 25 and 41% with 5 and 10 mM. However, for lower concentrations tested, the activity was reduced by 22 and 28%, respectively, with 0.5 and 1 mM with 1; no reduction of the activity was observed with Ac-Ala-Ala-Ala-Ala-OH at these concentrations, showing that 1 has a higher affinity for ACPH compared with Ac-Ala-Ala-Ala-Ala-OH.

Knockdown of ACPH protein expression with siRNA

To further define the role of ACPH in the ALA peptide derivative hydrolysis, RNA interference for ACPH was employed by transfection of cells with the specific siRNA against murine ACPH mRNA (Figure 8). Inhibition of the ACPH protein expression by siRNA reduced the PpIX production significantly by 53% after incubation with compound 1. However, when cells were incubated
with ALA, the PpIX production was only reduced by 25%. These results convincingly indicate that the expression of ACPH protein is involved in the hydrolysis of ALA peptide derivatives.

**DISCUSSION**

The targeted delivery of anticancer drugs to specific cell types, including photosensitisers in PDT, is of crucial importance for minimising treatment side effects. For the ALA prodrugs to exert a pharmacological effect, the derivatives must be able to reach the target sites at a sufficient concentration; this depends on the presence on the target cells of the necessary transport systems able to deliver them into the cytoplasm (Doring et al., 1998; Langer et al., 1999; Novotny et al., 2000; Rud et al., 2000; Irie et al., 2001) and their ability to undergo an efficient enzymatic hydrolysis to liberate ALA for the subsequent conversion to protoporphyrin IX (Peng et al., 1996).

A major challenge in ALA-PDT at the present time is the need to achieve a more effective penetration of ALA into target tissues or the cells of pathogenic organisms. A limitation to the use of ALA in PDT results from its low lipid solubility, a consequence of its zwitterionic character at physiological pH that leads to poor penetration through biological barriers such as cellular membranes. This problem has partly been addressed through the synthesis of lipophilic ester prodrugs that provide improved
Metabolism studies of S-ALA peptide derivatives

L Bourré et al

Presence or absence of an N-terminal blocking group, compared with ALA itself (Figure 1). The presence of the N-acetyl group at the N terminus of compounds 1–7 prevents decomposition of the derivative at physiological pH. Consequently, these peptide derivatives do not need to be prepared and then dissolved as hydrochloride salts, unlike ALA. We have also prepared the corresponding non-acetylated derivatives, 8 (L-Phe-ALA-Me) and the free acid 9 (L-Phe-ALA). However, these compounds show limited stability, presumably due to the cyclisation of the N-terminal amino group of phenylalanine onto the carbonyl moiety of the ALA residue, generating a six-membered Schiff base intermediate that may react further (Berger et al, 2003), which therefore necessitates preparation just before the experiment.

The determination of protoporphyrin IX production (Figure 2) showed that compounds 1–6 were found to be capable of being taken up by cells and releasing ALA for subsequent conversion to PpIX, with a significant enhancement of PpIX production compared with ALA for compounds 1, 6, 5, 4 and 3, respectively. The effect of modification of the prodrg structure at the C or N terminus on PpIX production, compared with ALA, was then studied. Fluorescence spectroscopy was employed to detect and quantify the PpIX accumulation induced by the compounds 1 and 7–10 vs ALA in the transformed keratinocyte PAM212 cell line. Compound 7 (Figure 3), corresponding to the free acid of compound 1, showed a significant increase compared with ALA, with a PpIX level comparable with compound 1. However, 8 and 9, compounds without an acetyl group at the N terminus, induced less PpIX compared with ALA. The acetyl group at the N terminus, therefore, seems to play an important role, in metabolic processes leading to the production of PpIX, whereas masking the C terminus as a methyl ester does not exert a major effect. In agreement with the fluorescence pharmacokinetic data, photodynamic treatment of cells incubated with ALA, 1, 6, 7, 8 and 9 (Figure 5) showed that the photocytotoxicity correlated with the PpIX fluorescence level described in Figure 3A. Following the illumination of cells incubated with compounds 1, 6 and 7, cell survival was significantly reduced (Figure 5) compared with equimolar ALA. However, ALA, 8 and 9 exhibited no photocytotoxicity in agreement with the lack of porphyrin produced by these compounds.

Substitution (compound 10) on the N terminus by a benzyl-oxyxycarbonyl (Z) group, instead of the acetyl group, abolished the activity of the compound with no PpIX production observed, as shown in Figure 4A. In pig skin explants, we have shown earlier cellular uptake and are metabolised into PpIX following the action of nonspecific intracellular esterases (Lopez et al, 2004). A more recent development concerns the preparation of peptide-based ALA prodrgs, and we (Casas et al, 1999; Rogers et al, 2005) and others (Berger et al, 2000, 2003) have described the synthesis and evaluation of short ALA peptide derivatives in which either the amino or the carboxyl functions of the latter are masked, thereby providing improved physical properties and the potential for cell line-specific ALA release, according to which peptidases are expressed. We have shown earlier the feasibility of using L-phenylalanyl-ALA derivatives (Bourré et al, 2008) to enhance intracellular porphyrin production and improve the efficacy of photodynamic treatment.

In this study, we investigated the properties of a larger number of ALA peptide derivatives containing different amino acids and studied the influence of structural modification in the form of the

Figure 7 Inactivation of acylpeptide hydrolase by thiol reagent pHMB (A) and histidine-modifying reagent DEP (B). Cellular extracts were incubated with 0 min (●), 0.01 min (▲), 0.05 min (▲), 0.2 min (▲) and 0.5 min (▲) of pHMB or DEP. (C) Influence of ALA (*), Ac-Ala-Ala-Ala-Ala-OH (▲) and 1 (■) on acylpeptide hydrolase activity. Cellular extracts were preincubated with a range of concentration of prodrgs during 1 h, then the enzyme activity was determined with AANA as substrate as described earlier after 30 min.

Figure 8 Relative PpIX production (%) in PAM212 cells treated with siRNA directed towards ACPH mRNA. Seventy-two hours after transfection, cells were incubated with 0.5 mM of ALA or 1 during 4 h at 37°C. Error bars show standard deviations. *P<0.01 (vs no transfected cells).
neutral amino-acid residues at the N terminus. In agreement with cytoplasm, show a strong preference for substrates that contain the involvement of aminopeptidase N/M activity in ALA el al (2000) have described the evaluation of several t-N derivatives here, Berger et al (2000) observed no PpIX production in cells from peptide derivatives in which the N terminus was blocked with an alkoxycarbonyl group (t-butoxycarbonyl, Boc). Such derivatives are not expected to be substrates for aminopeptidase N/M. Uncapped compounds 8 and 9, which are potential substrates for aminopeptidase N/M, showed low PpIX production. We did, however, find that PAM212 cells had APN/M activity using the specific substrates H-Ala-/fNA, H-Phe-/fNA and H-Leu-/fNA (data not shown), suggesting that the lack of PpIX production with 8 and 9 may be due to poor cellular uptake.

We also studied the influence of the aminopeptidase inhibitors (amastatin, bestatin and aminopeptidase N inhibitor) on PpIX production with 1 (data not shown), but none of them were able to reduce the PpIX production, confirming that the N-acetyl ALA peptide derivatives studied here should not be substrates for aminopeptidases and that these enzymes are not involved in the mechanism of ALA release from these ALA peptide derivatives. It is more probable that endopeptidases or exopeptidases, which can act on N-terminally acylated derivatives, are involved. On the basis of the results described here, it is probable that the N-acetylated amino-acid residue is cleaved to release ALA or ALA-Me for conversion to PpIX. We hypothesised that the acylpyridyl residue is most likely released by the acylpyridyl hydrolase (ACPH, EC 3.4.19.1), a member of the prolyl oligopeptidase family of serine peptidases, and an exopeptidase that removes acylated amino-acid residues from the N terminus of oligopeptides.

To obtain further information concerning the enzymatic activities involved in releasing free ALA from these precursors, we evaluated PpIX production in the presence of class-specific protease inhibitors (Figure 6): protease inhibitor cocktail, aprotinin, AEBSF, 2,2'-bipyridyl, bestatin, E64, leupeptin and captopril. The PpIX production was reduced by the serine protease inhibitors, aprotinin and AEBSF.

The ACPH activity of the PAM212 cellular extract was then assessed using pACNA as a substrate (Scalon et al, 1992b, 1994; Sharma and Ortweth, 1993; Yamaguchi et al, 1999). The PAM212 cell lysate showed some ACPH activity in the absence of inhibitors. However, the ACPH activity was rapidly and completely inhibited by pHMB (Figure 7A) and moderately by DEP (Figure 7B). The influence of preincubation of cells with ALA peptide derivative on the ACPH activity was studied, showing that compound 1 induced a reduction of the activity by 41% at 10 mM. These results were similar to those obtained with Ac-ALA-Ala-Ala-OH, an ACPH substrate, and are therefore consistent with the involvement of the serine protease ACOPH in ALA release from ALA-containing peptide derivatives.

The final functional argument to prove the causal relationship between ACPH expression/activity and ALA peptide derivative hydrolysis inducing the PpIX formation is now provided by the fact that the PpIX formation can be reduced by siRNA interference directed towards ACPH (Figure 8). Sequence-specific post-transcriptional gene silencing by double-stranded RNA (dsRNA), also called RNA interference, is conserved in a diverse variety of organisms (Gupta et al, 2004). RNA interference is mediated by siRNAs that are produced endogenously from long dsRNAs of exogenous or endogenous origin by an endonuclease of the ribonuclease-III type. The resulting siRNAs are 21–23 nucleotides long and are incorporated into a nuclease complex. After binding to the RNA-induced silencing complex, complementary mRNA is cleaved (Elbashir et al, 2001). Here, we described siRNA sequences effective in reducing ACPH expression on reverse transfection, leading to a significant PpIX reduction by 53% with compound 1. These results confirm that the expression of ACPH protein is involved in the hydrolysis of the ALA peptide derivatives. Moreover, it is known that the enzyme is preferentially directed towards peptides with Ac-Ala- and Ac-Met-, and tolerates a variety of residues in the second position (P2) (Jones and Manning, 1988; Radhakrishna and Wold, 1989; Krishna and Wold, 1992; Sokolik et al, 1994; Raphel et al, 1999). This is consistent with the results obtained with compound 6 corresponding to methionyl derivative, which shows a higher PpIX enhancement compared with the other derivatives, apart from 1, which also induces similar levels of PpIX. Compound 3, corresponding to the alanyl derivative, induced a PpIX enhancement compared with ALA but not as high as that of the methionyl or phenylalanyl derivative. However, this result does not reflect the ACPH substrate specificity described in the literature (Kobayashi and Smith, 1987; Krishna and Wold, 1992; Sokolik et al, 1994), in which it was found that Ac-Ala-Ala-Ala is the substrate that exhibits the highest hydrolysis efficiency. The hydrolysis parameters were generally determined on specific sequences by studying the influence of the position of one amino acid in the sequence on the hydrolysis rate. In the case of the compounds studied here, no corresponding data are available for the ACPH activity towards peptides including 5-ALA, which mimic Gly-Gly dipetidates, that is with a general sequence Ac-aa-Gly-Gly. These discrepancies need to be examined in terms of the sequence in which the presumed specificity-determining amino acids were displayed in the different substrates, and it would be an oversimplification to merely state that ACPH requires a given residue in position P1, P1', P2 and so on. One also has to consider how the activity will be interdependent on the presence of these residues in conjunction with all the other constituents of the peptide substrate. A further potentially important factor is that owing to the presence of the phenyl group, the phenylalanyl derivative is more lipophilic than the alanyl derivative, which should enhance the relative cellular uptake of the phenylalanyl derivative and therefore the measured porphyrin production.

In conclusion, the results in this study provide further evidence that the conjugation of ALA with specific amino acids is a promising approach for inducing enhanced intracellular porphyrin production for photodynamic therapy. As peptidase expression is generally different between normal and tumour cells or tissues, there is the possibility of more specific targeting, particularly by modulating the N-terminal portion. Our derivatives showed a specific affinity for ACPH, an enzyme the expression of which is higher in tumour cells compared with normal cells (Schoenberger et al, 1986). Indeed, although ACPH activity is practically absent in A549 small-cell lung carcinoma cells (Scalon et al, 1992a), we were still able to observe low levels of PpIX production after incubation with compound 1 (data...
not shown). The peptide prodrugs described herein may be suitable for both topical use (e.g. for bladder and cervical cancers in addition to basal cell carcinomas) and for systemic administration in view of their low inherent toxicity (Bourré et al, 2008) compared with the hexyl ester of ALA. Further studies to optimise peptide-based ALA delivery are currently in progress using more complex ALA-containing amino-acid sequences and cell-penetrating peptide carriers (Dixon et al, 2007).

REFERENCES

Battah S, O’Neill S, Edwards C, Balaratnam S, Dobbin P, MacRobert AJ (2006) Enhanced porphyrin accumulation using dendritic derivatives of 5-aminolaevulinic acid for photodynamic therapy: an in vitro study. Int J Biochem Cell Biol 38: 1382 – 1392
Battah SH, Chee CE, Nakanishi H, Gerscher S, MacRobert AJ, Edwards C (2001) Synthesis and biological studies of 5-aminolaevulinic acid-containing dendrimers for photodynamic therapy. Bioconjng Chem 12: 980 – 988
Berger Y, Greppi A, Siri O, Neier R, Juillerat-Jeanneret L (2000) Ethylene glycol and amino acid derivatives of 5-aminolaevulinic acid as new photosensitizing precursors of protoporphyrin IX in cells. J Med Chem 43: 4738 – 4746
Berger Y, Ingrassia L, Neier R, Juillerat-Jeanneret L (2003) Evaluation of dipeptide-derivatives of 5-aminolaevulinic acid as precursors for photosensitizers in photodynamic therapy. Bioorg Med Chem 11: 1343 – 1351
Bonnett R (1995) Photosensitizers of the porphyrin and phthalocyanine series for photodynamic therapy. Chem Soc Rev 24: 19 – 33
Bourré L, Giuntini F, Wilson M, Eggleston IM, MacRobert AJ (2008) 5-Aminolaevulinic acid peptide prodrugs enhance photosensitisation for photodynamic therapy. Mol Cancer Ther 7: 1720 – 1729
Brown SB, Brown EA, Walker I (2004) The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 5: 497 – 508
Brunner H, Haussmann F, Knuechel R (2003) New 5-aminolaevulinic acid esters – efficient protoporphyrin precursors for photodetection and photodynamic therapy. Photochem Photobiol 78: 481 – 486
Casas A, Battle A (2006) Aminolaevulinic acid derivatives and liposome delivery as strategies for improving 5-aminolaevulinic acid-mediated photodynamic therapy. Curr Med Chem 13: 1157 – 1168
Casas A, Battle AMD, Butler AR, Robertson D, Brown EH, MacRobert A, Riley PA (1999) Comparative effect of ALA derivatives on protoporphyrin IX production in human and rat skin organ cultures. Br J Cancer 80: 1525 – 1532
Casas A, Perotti C, Saccoliti M, Sacca P, Fukuda H, Batlle AM (2002) ALA and ALA hexyl ester in free and liposomal formulations for the photosensitisation of tumour organ cultures. Br J Cancer 86: 837 – 842
Di Venosa GM, Cassa AG, Battah S, Dobbin P, Fukuda H, MacRobert AJ, Battle A (2006) Investigation of a novel dendritic derivative of 5-aminolaevulinic acid for photodynamic therapy. Int J Biochem Cell Biol 38: 82 – 91
Dixon MJ, Bourre L, MacRobert AJ, Eggleston IM (2007) Novel prodrug approach to photodynamic therapy: Fmoc solid-phase synthesis of a cell permeable peptide incorporating 5-aminolaevulinic acid. Bioorg Med Chem Lett 17: 4518 – 4522
Doring F, Walter J, Will J, Focking M, Boll M, Amashch S, Claus W, Daniel H (1998) Delta-aminolaevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J Clin Invest 101: 2761 – 2767
Elbashir SM, Lendeckel W, Tuschl T (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15: 188 – 200
Eleoet S, Rousett N, Carre J, Bourre L, Vonarx V, Lajat Y, Beijersbergen van Henegouwen GM, Patrice T (2000) In vitro fluorescence, toxicity and phototoxicity induced by delta-aminolaevulinic acid (ALA) or ALA-esters. Photochem Photobiol 71: 447 – 454
Gaulier JM, Berg K, Peng Q, Anholt H, Selbo PK, Ma LW, Moan J (1997) Use of 5-aminolaevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res 57: 1481 – 1486
Gupta S, Schoer RA, Egan JE, Hannon GJ, Mittal V (2004) Inducible, reversible, and stable RNA interference in mammalian cells. Proc Natl Acad Sci USA 101: 1927 – 1932
Irie M, Terada T, Sawada K, Saito H, Inui K (2001) Recognition and transport characteristics of nonpeptidic compounds by basolateral peptide transporter in Caco-2 cells. J Pharmacol Exp Ther 298: 711 – 717
Jones WM, Manning JM (1988) Substrate specificity of an acylaminopeptidase that catalyzes the cleavage of the blocked amino termini of peptides. Biochem Biophys Acta 953: 357 – 360
Kloek J, Akkermans W, van Henegouwen GMJB (1998) Derivatives of 5-aminolaevulinic acid for photodynamic therapy: enzymatic conversion into protoporphyrin. Photochem Photobiol 67: 150 – 154
Kloek J, Beijersbergen VH (1996) Prodrugs of 5-aminolaevulinic acid for photodynamic therapy. Photochem Photobiol 64: 994 – 1000
Kobayashi K, Smith JA (1987) Acetyl-peptide hydrolase from rat liver. Characterization of enzyme reaction. J Biol Chem 262: 11435 – 11445
Krishna RG, Wold F (1992) Specificity determinants of acylamoacyl-peptide hydrolase. Protein Sci 1: 582 – 589
Langer S, Abels C, Botzlar A, Pahernik S, Rick K, Szeimies RM, Goetz AE (1999) Active and higher intracellular uptake of 5-aminolaevulinic acid in tumors may be inhibited by glycine. J Invest Dermatol 112: 723 – 728
Lopez RF, Lange N, Guy R, Bentley MV (2004) Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv Rev 56: 77 – 94
Novotny A, Xiang J, Stummer W, Teuscher NS, Smith DE, Keep RF (2000) Mechanisms of 5-aminolaevulinic acid uptake at the choroidal plexus. J Neurochem 75: 321 – 328
Peng Q, Moan J, Warloe T, Iani V, Steen HB, Rjorsæth A, Nesland JM (1996) Build-up of esterified aminolaevulinic acid-derivative-induced porphyrin fluorescence in normal mouse skin. J Photochem Photobiol B 34: 95 – 96
Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, Nesland JM (1997) 5-aminolaevulinic acid-based photodynamic therapy – clinical research and future challenges. Cancer 79: 2282 – 2308
Radhakrishna G, Wold F (1989) Purification and characterization of an N-acylaminoacyl-peptide hydrolase from rabbit muscle. J Biol Chem 264: 11076 – 11081
Raphael V, Giardina T, Guevel L, Perrier J, Dupuis L, Guo XJ, Puigserver A (1999) Cloning, sequencing and further characterization of acylypside hydrolase from porcine intestinal mucosa. Biochim Biophys Acta 1432: 371 – 381
Rogers LMA, McGivern PG, Butler AR, MacRobert AJ, Eggleston IM (2005) An efficient synthesis of 5-aminolaevulinic acid (ALA)-containing peptides for use in photodynamic therapy. Tetrahedron 61: 6951 – 6958
Rud E, Gederaas O, Hogset A, Berg K (2000) 5-aminolaevulinic acid, but not 5-aminolaevulinic acid esters, is transported into adenocarcinoma cells by system BETA transporters. Photochem Photobiol 71: 640 – 647
Scaloni A, Barra D, Jones WM, Manning JM (1994) Human acylpeptide hydrolase. Studies on its thiol groups and mechanism of action. J Biol Chem 269: 15076 – 15084
Scaloni A, Jones W, Pospischil M, Sassa S, Schneewind O, Popowicz AM, Bossa F, Graziano SL, Manning JM (1992a) Deficiency of acylpeptide hydrolase in small-cell lung carcinoma cell lines. J Lab Clin Med 120: 546 – 552
Scaloni A, Jones WM, Barra D, Pospischil M, Sassa S, Popowicz A, Manning LR, Schneewind O, Manning JM (1992b) Acylpeptide hydrolase: inhibitors and some active site residues of the human enzyme. J Biol Chem 267: 3811 – 3818
Schoenberger OL, Schwobel H, Ebert W (1986) N-acetylatedalamine aminopeptidase activity in normal and tumour cells. J Clin Chem Clin Biochem 24: 375 – 378
Sharma KK, Orterwth BJ (1993) Bovine lens acylpeptide hydrolase. Purification and characterization of a tetrameric enzyme resistant to urea denaturation and proteolytic inactivation. Eur J Biochem 216: 631 – 637

ACKNOWLEDGEMENTS

We gratefully acknowledge the assistance of Noreen Farrowqui in carrying out this study and materials provided by Dr Sandy Mosse. We are grateful to Dr Marilena Loizidou for helpful discussions. This work was supported by Biotechnology and Biological Sciences Research Council grants BBD0127831 (IM Eggleston) and BBD0113291 (AJ MacRobert, M Wilson).
Sokolik CW, Liang TC, Wold F (1994) Studies on the specificity of acetylaminoacyl-peptide hydrolase. *Protein Sci* 3: 126–131

Uehlinger P, Zellweger M, Wagnieres G, Juillerat-Jeanneret L, van den BH, Lange N (2000) 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. *J Photochem Photobiol B* 54: 72–80

Webber J, Kessel D, Fromm D (1997) Side effects and photosensitization of human tissues after aminolevulinic acid. *J Surg Res* 68: 31–37

Yamaguchi M, Kambayashi D, Toda J, Sano T, Toyoshima S, Hojo H (1999) Acetylleucine chloromethyl ketone, an inhibitor of acylpeptide hydrolase, induces apoptosis of U937 cells. *Biochem Biophys Res Commun* 263: 139–142